IN THE CLAIMS:

Please amend claim 23, replacing the word "or" with a comma, as follows:

1-22. (Cancelled).

23. (Currently Amended) A synthetic immunogen for inducing specific antibodies against GnRH comprising:

(i) a promiscuous helper T-lymphocyte epitope selected from the group consisting of SEQ ID NO: 8 of measles virus protein F (MVP-F), SEQ ID NO: 2, [[or]] SEQ ID NO: 4 of tetanus toxoid (TT), and SEQ ID NO: 3 of malaria circumsporozoite protein (M-CSP), fused through

(ii) a spacer peptide selected from the group consisting of Gly-Pro-Ser-Leu (SEQ ID NO: 5), Ser-Ser-Gly-Pro-Ser-Leu (SEQ ID NO: 6), and Ser-Ser-Gly-Pro-Ser-Leu-Lys-Leu (SEQ ID NO: 7) to

(iii) a GnRH immunomimic peptide comprising either the amino acid sequence of SEQ ID NO: 1, or amino acids 2-10 of SEQ ID NO: 1.

24. (Original) The synthetic immunogen of claim 23, wherein the T-lymphocyte epitope is fused through the spacer peptide to the amino-terminus or the carboxy-terminus of the GnRH-immunomimic peptide.

25. (Original) The synthetic immunogen of claim 24, further comprising a second GnRH immunomimic peptide, wherein the second GnRH immunomimic peptide is fused at its carboxy-terminus or its amino-terminus through a spacer peptide to the T-lymphocyte epitope.

26. (Original) The synthetic immunogen of claim 23 wherein the T-lymphocyte epitope is fused through a spacer peptide to the amino-terminus of the GnRH-immunomimic peptide.

27. (Original) The synthetic immunogen of claim 23 comprising a GnRH-immunomimic peptide having an acetylated amino-terminal glutamic acid or an amidated carboxy-terminal glycine.

28. (Original) A synthetic immunogen for inducing specific antibodies against GnRH comprising a promiscuous helper T-lymphocyte epitope fused through a spacer peptide to a GnRH immunomimic peptide selected from the group consisting of the peptide defined by SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

29. (Original) The synthetic immunogen of claim 28, wherein the synthetic immunogen is the peptide defined by SEQ ID NO: 10 or SEQ ID NO: 11.

30. (Original) A combination of synthetic immunogens for inducing specific antibodies against GnRH comprising at least two different synthetic immunogens selected from the group consisting of the peptide defined by SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

31. (Original) The combination of synthetic immunogens according to claim 30, comprising:

(i) the synthetic immunogen defined by SEQ ID NO: 10; and

(ii) the synthetic immunogen defined by SEQ ID NO: 11.

32. (Original) An injectable pharmaceutical composition comprising the synthetic immunogen of claim 23, and a pharmaceutically acceptable carrier.

33. (Original) The injectable pharmaceutical composition of claim 32, comprising a synthetic immunogen selected from the group consisting of the peptide defined by SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID

NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20; and a pharmaceutically acceptable carrier.

34. (Original) The injectable pharmaceutical composition of claim 33, comprising the synthetic immunogen defined by SEQ ID NO: 10 or SEQ ID NO: 11; and a pharmaceutically acceptable carrier.

35. (Original) An injectable pharmaceutical composition comprising the combination of synthetic immunogens of claim 30, and a pharmaceutically acceptable carrier.

36. (Original) The injectable pharmaceutical composition of claim 35, comprising:

(i) the synthetic immunogen defined by SEQ ID NO: 10;

(ii) the synthetic immunogen defined by SEQ ID NO: 11; and

(iii) a pharmaceutically acceptable carrier.